Sid Mukher­jee's Vor adds clin­i­cal man­u­fac­tur­ing fa­cil­i­ty at ex­ist­ing Boston-area site, beef­ing up for a com­mer­cial push

When Sid­dhartha Mukher­jee found­ed Vor Bio­phar­ma in 2016, he had the goal of rewrit­ing the book on stem cell trans­plants. To get there, Vor need­ed a leg up in clin­i­cal man­u­fac­tur­ing — and now it has one.

Vor will build an in-house clin­i­cal man­u­fac­tur­ing fa­cil­i­ty next to its Cam­bridge, MA head­quar­ters, which is an­tic­i­pat­ed to be up and run­ning in 2022, the com­pa­ny said Thurs­day. The out­lay is all out of pock­et, but Vor says the build­out won’t im­pact its cash run­way, which is suf­fi­cient to ear­ly 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER